Li Li, Xu Yi, Yu Chun-Xia
Department of Gynecology, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Asian Pac J Cancer Prev. 2012;13(7):3265-70. doi: 10.7314/apjcp.2012.13.7.3265.
Clinically, elevated cancer antigen 125 (CA-125) in blood predicts tumor burden in a woman's body, especially in the ovary, but cannot differentiate between malignant or benign. We here used intensive modern proteomic approaches to identify predictive proteins in the serum of women with elevated CA-125 to differentiate malignant from benign ovarian tumors. We identified differentially expressed proteins in serum samples of ovarian cancer (OC) patients, benign ovarian tumor (BT) patients, and healthy control women using mass spectrometry-based quantitative proteomics. Both the OC and BT patients had elevated CA-125. Quantitation was achieved using isobaric tags for relative and absolute quantitation. We obtained 124 quantified differential serum proteins in OC compared with BT. Two proteins, apolipoprotein A-4 (APOA4) and natural resistance-associated macrophage 1, were verified using Western blotting. Proteome profiling applied to OC cases identified several differential serum proteins in the serum of women with elevated CA-125. A novel protein, APOA4, has the potential to be a marker for malignant tumor differentiation in the serum of women with elevated CA-125.
临床上，血液中癌抗原125（CA-125）升高可预测女性体内的肿瘤负荷，尤其是卵巢中的肿瘤负荷，但无法区分恶性或良性。我们在此使用密集的现代蛋白质组学方法，在CA-125升高的女性血清中鉴定预测性蛋白质，以区分恶性和良性卵巢肿瘤。我们使用基于质谱的定量蛋白质组学方法，在卵巢癌（OC）患者、良性卵巢肿瘤（BT）患者和健康对照女性的血清样本中鉴定差异表达的蛋白质。OC和BT患者的CA-125均升高。使用同重异位标签进行相对和绝对定量以实现定量。与BT相比，我们在OC中获得了124种定量的差异血清蛋白。使用蛋白质印迹法验证了两种蛋白质，即载脂蛋白A-4（APOA4）和天然抗性相关巨噬蛋白1。应用于OC病例的蛋白质组分析在CA-125升高的女性血清中鉴定出几种差异血清蛋白。一种新的蛋白质APOA4有可能成为CA-125升高女性血清中恶性肿瘤分化的标志物。
